BioSpace

Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success

Beam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA application as early as this year.

By BioSpace

1 min read
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights